Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1995-7-27
|
| pubmed:abstractText |
Hypercalcemia of malignancy is due either to local osteolysis at the site of bone metastases or to production by the malignancy of parathyroid hormone-related peptide, which shares some of the effects of parathyroid hormone. We used a radioimmunoassay (antiserum specific to the amino-terminus) to measure serum parathyroid hormone-related peptide levels in controls (n = 61), chronic renal failure patients (n = 10), patients with primary hyperparathyroidism (n = 19), cancer patients with (n = 35) or without (n = 57) hypercalcemia and/or bone metastases (n = 53 and n = 39, respectively), and patients with hematologic malignancies (n = 15). We set the upper limit of normal of the parathyroid hormone-related peptide assay at 2.7 pmol/L. The peptide was undetectable in two-thirds of healthy controls. Renal failure did not interfere with the assay. Eighteen of the 19 patients with primary hyperparathyroidism had normal levels. In contrast, 82% of patients with humoral hypercalcemia of malignancy (i.e., without detectable bone metastases) had increased levels; in this subgroup there was a significant inverse correlation between serum levels of the peptide and phosphorus. Elevation of parathyroid hormone-related peptide levels was less common among hypercalcemic patients with metastatic bone disease (38%). Four of the seven hypercalcemic patients with hematologic malignancies had elevated parathyroid hormone-related peptide levels. In our overall study population, serum calcium levels were weakly but significantly correlated with parathyroid hormone-related peptide levels. In conclusion, elevated parathyroid hormone-related peptide in a patient with hypercalcemia suggests a malignant disease.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/PTHLH protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone-Related Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1169-8446
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
62
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
189-96
|
| pubmed:dateRevised |
2006-6-29
|
| pubmed:meshHeading |
pubmed-meshheading:7788336-Adult,
pubmed-meshheading:7788336-Aged,
pubmed-meshheading:7788336-Bone Neoplasms,
pubmed-meshheading:7788336-Calcium,
pubmed-meshheading:7788336-Female,
pubmed-meshheading:7788336-Hematologic Diseases,
pubmed-meshheading:7788336-Humans,
pubmed-meshheading:7788336-Hypercalcemia,
pubmed-meshheading:7788336-Hyperparathyroidism,
pubmed-meshheading:7788336-Kidney Failure, Chronic,
pubmed-meshheading:7788336-Male,
pubmed-meshheading:7788336-Middle Aged,
pubmed-meshheading:7788336-Neoplasms,
pubmed-meshheading:7788336-Parathyroid Hormone,
pubmed-meshheading:7788336-Parathyroid Hormone-Related Protein,
pubmed-meshheading:7788336-Proteins,
pubmed-meshheading:7788336-Radioimmunoassay,
pubmed-meshheading:7788336-Reference Values
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia.
|
| pubmed:affiliation |
Department of Rheumatology, Angers Teaching Hospital, France.
|
| pubmed:publicationType |
Journal Article
|